News | February 18, 2015

Radioactive Bead Therapy Now Used for Head, Neck Tumors

Holmium beads offer pinpoint radiation dispersal, can be monitored through multiple modalities

holmium beads, radiation therapy, UMC Utrecht, radiopharmaceuticals, tracers

February 18, 2015 — Researchers at University Medical Center (UMC) Utrecht are developing an innovative cancer treatment involving the injection of radioactive beads into tumors, thereby enabling a very precise localized radiotherapy. The treatment is being developed with the help of a grant from Alpe d’HuZes/Dutch Cancer Society (KWF) of nearly 300,000 euros.

Direct injection of radioactive beads may be an effective treatment of tumors that are difficult or impossible to remove surgically. This is the basic principle of medical biologist Frank Nijsen, M.D., dental surgeon Robert van Es, M.D., and nuclear physician Marnix Lam, M.D., of UMC Utrecht. They are working together with Bas van Nimwegen, M.D., of the Faculty of Veterinary Medicine of Utrecht University to treat head and neck tumors with radioactive beads.

The treatment involves holmium microspheres that appear on a magnetic resonance imaging (MRI) or a nuclear scan. Using image-guided injection, the microspheres can be inserted into a tumor in a highly precise and localized fashion. In the first three millimeters, the holmium microspheres emit 90 percent of their radiation. The treatment is radically different from similar approaches involving radioactive yttrium microspheres. Holmium microspheres can be located using MRI, computed tomography (CT) and nuclear imaging techniques. This enables improved monitoring of the holmium treatment’s safety and effectiveness.

In collaboration with the Faculty of Veterinary Medicine of Utrecht University the treatment is now being tested in pets with tumors. The preliminary results are positive. Over the past four years, 15 cats and dogs have been treated for predominantly aggressive tongue tumors. The treatment was effective in the majority of animals. On average, tumor size was reduced by 80 percent and the tongue could still be used.

“The results in these animal patients are very promising,” said Ron Koole, M.D., of the Department of Oral and Maxillofacial Surgery of UMC Utrecht. “That is why I brought together scientists working on this subject to make the treatment available to human cancer patients as well."

The grant from Alpe d’HuZes/KWF will be used by the Utrecht researchers to expand their activities in this field. This should result in a phase I clinical trial studying the safety of the treatment in cancer patients. One of the most important questions is how these microspheres should be injected in order for them to effectively spread within the tumor and produce maximum effect. Possible side effects of the treatment should also be identified.

“Head and neck tumors are of course only one application of this treatment,” says Frank Nijsen, M.D., of UMC Utrecht. “In principle, it is possible to treat any fixed tumor that can be reached with a needle with holmium microspheres. However, we first need to prove that we can inject tumors repeatedly and in a controlled manner.”

For more information: www.umcutrecht.nl

Related Content

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Feature | Radiation Oncology | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 20 pieces of radiation oncology content on the Imaging Technology News (ITN) websit